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Purpose: We evaluated the safety and effectiveness of the Magnetic Resonance-
guided Focused Ultrasound (MRgFUS) with the ExAblate Conformal Bone System 
for the palliation of painful bone metastases. Materials and Methods: Our Institu-
tional Review Board approved this study, and all patients gave informed consent 
prior to enrollment. A total of six painful metastatic bone lesions in five patients 
were treated using MRgFUS with the ExAblate Conformal Bone System for pain 
palliation. The follow-up sessions were at 3 days, 2 weeks, 1, 2, and 3 months, and 1 
year after treatment. Efficacy was evaluated by the changes in visual analog scale 
(VAS) scores. At 3-months and 1-year follow-ups, unenhanced computed tomogra-
phy and contrast-enhanced MR imaging examinations were performed. All adverse 
events were assessed to evaluate treatment safety. Results: All patients showed sig-
nificant pain relief within 2 weeks. Two patients experienced complete pain reduc-
tion that lasted for 1 year. Two other patients showed pain relief measured as VAS 
scores of 2 and 4 on their last follow-up. Although the remaining patient had experi-
enced significant pain relief in two lesions, the VAS score re-increased on his last 
follow-up. The size of the enhancing soft tissue mass in metastatic lesions de-
creased, and new bone formation was seen on follow-up images. Although adverse 
events were not serious, non-specific leg pain and second degree skin burn were 
noted. Conclusion: MRgFUS was demonstrated to be effective palliative treatment 
within 2 weeks in selected patients with painful bone metastases.
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INTRODUCTION
Bone pain is the most common source of cancer-related pain in patients suffering 
from metastatic cancer.1,2 Current approaches to treating this condition include an-
algesics, chemotherapy, hormonal therapy, and bisphosphonates for systemic treat-
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MATERIALS AND METHODS
Study design and patient population
This study was approved by our Institutional Review Board, 
and informed consent was obtained from all patients prior 
to enrollment. The study was supported by a research grant 
from InSightec (Tirat Carmel, Israel); however, the authors 
had complete control of the data for the purpose of this study, 
with no influence from the company during the preparation 
of this manuscript.
From March to September 2012, six consecutive patients 
with painful bone metastases were enrolled in our study. 
One patient was excluded during the screening period due 
to disease progression that caused paralysis in both legs. 
Ultimately, five patients were treated with MRgFUS (two 
females, three males; average age, 60 years; range, 51‒68 
years). All patients had undergone chemotherapy before the 
enrollment. One lesion had been treated by RT previously. 
However, the RT had not been effective; therefore, MRg-
FUS treatment was performed on the lesion. One patient 
was treated twice with MRgFUS for two different lesions, 
which were conducted about a month apart.
The main inclusion criteria were painful bone metastases 
with an Numerical Rating Scale pain score of 4 or higher 
and five or fewer distinguishable lesions, each of which 
were clearly visible on non-contrast MRI and accessible to 
the conformal bone system. The critical exclusion criteria 
were standard contraindications to MR imaging or gadolin-
ium-based contrast agents, active infection or severe sys-
temic disease (excluding the primary malignancy), and tar-
get tumors at an impending fracture site of weight-bearing 
bone or at a depth of less than 1 cm under the skin.
Imaging protocol
Baseline CT and MR images were obtained to identify the 
tumor size and location, adjacent anatomic structures, and 
device accessibility. Unenhanced CT imaging (100‒120 kV 
with automated tube current modulation; kernel, B31f; win-
dow level, 570 HU; window width, 3000 HU; slice thick-
ness, 3‒5 mm; Somatom with CARE Dose4D; Siemens 
Medical Solutions, Forchheim, Germany) was performed if 
pre-screening CT images within 1 month before enrollment 
were not available. MR images included pre-contrast T1-
weighted  sequences with fat suppression [fast spoiled gra-
dient-echo sequence, repetition time (ms)/echo time (ms), 
355/2.18; field of view, 36; matrix, 256×256; band-width, 
ment; additionally, radiation therapy, percutaneous ablative 
methods, and surgical stabilization may be used for local 
control.3-5
Although treatment with external beam radiation therapy 
(RT) is the current standard of care for patients with painful 
bone metastases, RT has not been effective in 20% to 30% 
of patients treated with this modality, and re-treatment rates 
have been generally reported in the range of 10‒25%.6-9 
Furthermore, repeating RT treatment at a site previously ir-
radiated may not be eligible due to limitations in normal tis-
sue radiation intolerance.10 
Magnetic Resonance-guided Focused Ultrasound (MRg-
FUS) is a completely noninvasive thermal ablation tech-
nique that enables physicians to perform localized ablation 
of intracorporeal tissue by focusing the acoustic energy 
precisely at the targeted volume. According to previous 
studies, MRgFUS used with a body system can be an ef-
fective and safe treatment option for patients suffering 
from painful bone metastases, especially those who fail to 
obtain adequate pain relief by other preceding therapies or 
cannot take other treatment due to poor physical and func-
tional status.8,11 
The development of MRgFUS devices for various clinical 
pathological conditions is still an ongoing process. One of 
the recently developed devices is the ExAblate 2100 Con-
formal Bone System (InSightec, Tirat Carmel, Israel), spe-
cifically designed for bone applications. Compared to the 
original fixed ExAblate 2000 Body System, where the ac-
tual transducer is embedded in the MR patient table, the 
transducer of ExAblate 2100 Conformal Bone System has 
an external connection to the MR patient table. This trans-
ducer is strapped onto the patient, who is then placed on the 
MRI table and moved into the MRI scanner. These new fea-
tures enable easy and comfortable access to multiple ana-
tomical locations, and the patient position is more comfort-
able as they can avoid lying on a painful body site, thereby 
decreasing pain experienced during treatment. In addition, 
this device is equipped with an electronically steerable trans-
ducer with a higher density (1000 elements), and an inte-
grated built-in skin cooling system that uses a cooled po-
rous membrane. There have been no reports on using this 
system for patients with bone metastasis that include a 
long-term follow up.
The goal of this prospective, non-randomized, single-arm 
study was to evaluate the safety and effectiveness of the 
ExAblate Conformal Bone System for the palliation of pain-
ful bone metastases.
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cooling system.
After patients were set up with the ExAblate Conformal 
Bone System by strapping the transducer over the targeted 
tumor, T2-weighted MR images in all three orientations 
were acquired to confirm that the transducer was in the cor-
rect location relative to the target. Upon completion of CT-
MR registration, which assists bone cortex identification, 
treatment volume was drawn, and the number of treatment 
sonications that was needed to complete the desired treat-
ment using the MRgFUS system was computed. Test soni-
cations with a low temperature rise were performed to en-
sure the targeting accuracy; then, sonications at a therapeutic 
power level were performed. Throughout the treatment, 
each sonication’s location and the temperature elevation in 
the tissue adjacent to the targeted bone were monitored in 
real-time (Fig. 1). Immediately after treatment, a series of 
MR scans including T2-weighted sequences and T1-weight-
ed contrast enhanced sequences were performed to evaluate 
the general anatomy, the extent of the thermal ablation, and 
the possibility of eventual unexpected adverse events after 
the ablative process. There were no differential planning 
options for osteolytic or mixed lesions available in the ver-
sion used for these treatments.
Assessment of treatment efficacy and safety
Patients were followed for a period of up to 1 year. The fol-
61.05; flip angle, 90°; section thickness, 4 mm] followed by 
gadolinium-enhanced (Gadodiamide, 10 mg; Omniscan, 
GE Healthcare, Mississauga, Ontario, Canada) T1-weight-
ed images with the same sequence. T2-weighted sequences 
with and without fat suppression (fast spin-echo sequence, 
6479/74; field of view, 36; matrix, 256×256; bandwidth, 
61.05; section thickness, 5 mm) were performed before the 
contrast-enhanced study. 
Treatment process
Before treatment, all patients underwent regional anesthesia 
using epidural or brachial plexus anesthesia according to 
the target tumor, and sedation was also administered to alle-
viate patients’ nervousness. 
MRgFUS treatments were carried out using a focused ul-
trasound phased array system (ExAblate 2100 System, In-
Sightec Ltd., Tirat Carmel, Israel) integrated with a clinical 
3.0-T MR Scanner (Discovery MR 750; GE Medical Sys-
tems, Milwaukee, WI, USA). This new version of the ExAb-
late Conformal Bone System has a flexible transducer as-
sembly that operates at a lower frequency (550 kHz) and 
has an acoustic power range of up to 200 W. In addition, it 
is equipped with an electronically steerable 1000-element 
transducer (focus steering range, ±35 mm; weight, 1.5 kg 
with water) and a water-permeable membrane to provide 
effective acoustic coupling and an integrated built-in skin 
Fig. 1. Procedure image. The continuous MR imaging system allows the physician to identify and target tumors and provides temperature 
monitoring of the treated tissue in real time.
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Conscious sedation was sufficient for five treatments, while 
one treatment required deep sedation (Table 1).
Patient 1 was treated at two different sites and followed-
up 60 days after treatment on the left iliac bone and 30 days 
after treatment on the right shoulder. Patients 2 and 3 were 
followed-up 1 year after treatment, while Patients 4 and 5 
were followed-up 60 and 30 days after treatment, respec-
tively. Two patients (Patient 1 and Patient 5) died before 
reaching the last follow-up session, and one patient (Patient 
4) was unable to visit for a 3-month CT and MRI due to 
rapid progression of systemic neoplastic disease.
Table 2 shows the changes in the worst VAS scores over 
time. Significant pain relief was achieved within 3 days 
(n=3), 7days (n=2), and 14 days (n=1). The two patients 
with breast cancer completed the scheduled follow-up (1 
year), and the worst VAS score at 1 year was 0. The three 
patients who could not complete the planned follow-up due 
to rapid progression of their primary cancer yielded the fol-
lowing worst VAS score changes: Patient 1 exhibited a re-
exacerbation in VAS score, Patient 4’s score remained at 
the same level as the early response, and Patient 5’s score 
was further reduced to 1.
Patient 1, who had right scapular pain, had limitations in 
the movement of his right arm and difficulty during meals. 
After the treatment, he had no more difficulty in using his 
right arm up to death, despite the re-increase in the VAS 
score. Patient 2, who had a metastatic lesion on the left iliac 
low-up sessions were at 3 days, 2 weeks, 1, 2, and 3 months, 
and 1 year after treatment. To evaluate efficacy and safety 
of the MRgFUS treatment, each follow-up section included 
an evaluation of patient status, changes in pain levels by vi-
sual analog scale (VAS) pain questionnaires, changes in an-
algesic medication intake, and any procedure-related ad-
verse event. Pain relief indicated by a VAS score of 2 or 
morewas defined as significant pain relief.
At 3-months follow-up, unenhanced CT and contrast-en-
hanced MR imaging examinations were performed (imag-
ing protocols were similar to those of baseline imaging).
RESULTS
 
A total of six painful metastatic bone lesions in five patients 
were treated by MRgFUS in this study. The primary tumor 
origins were the breast (n=2), kidney (n=1), liver (n=1), and 
trachea (n=1). The locations of treated bone lesions included 
the ilium (n=3), scapula (n=1), femur (n=1), and humerus 
(n=1). Five lesions were osteolytic, and one lesion was 
mixed type. The number of sonications was between 15 and 
20 times per treatment. The energy range of sonication was 
between 400 J and 4800 J, and the power range was between 
13 W and 160 W. The length of treatment ranged from 100 to 
180 minutes. Four treatments were conducted under epidural 
anesthesia, and two treatments used a brachial plexus block. 
Table 1. Patient and Targeted Lesion Characteristics 
Patient 
number Age Primary cancer
Metastatic lesion Tumor size (mm)
Power range 
(W)
Treatment 
timeLocation Type Pre-treatment
3-month 
follow-up
1-1
68 Cholangiocarcinoma
Left ilium Osteolytic 34.4 26‒59 2 hr 10 min
1-2 Right scapula Osteolytic 47.3 23‒58 3 hr
2 51 Breast cancer Left ilium Osteolytic 60.3 50.8 14‒68 1 hr 45 min
3 55 Breast cancer Right femur Mixed 27.4 23.0 40‒62 1 hr 40 min
4 58 Renal cell carcinoma Right humerus Osteolytic 31.9   25‒160 2 hr 40 min
5 67 Tracheal cancer Right ilium Osteolytic 55.0 13‒44 2 hr 40 min
Table 2. Changes in the Worst VAS Scores on Follow-Up
Patient 
number Primary cancer Metastatic lesion Initial
Post-treatment
Day 3 Day 7 Day 14 Day 30 Day 60 Day 90 Yr 1
1-1
Cholangiocarcinoma
Left ilium 4 2 1    2.5    3.5    4.5
1-2 Right scapula    5.5 5    3.5    2.5 4
2 Breast cancer Left ilium 7 5 4 2 2 2 0 0
3 Breast cancer Right femur 7 6 3 2 2 2    1.5 0
4 Renal cell carcinoma Right humerus 7 7 7 5 5 5
5 Tracheal cancer Right ilium 5 3 1 1 1
VAS, visual analog scale.
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one day after MRgFUS treatment; however, this symptom 
resolved spontaneously within 2 weeks without any specif-
ic treatment. On the MRIs taken immediately and 90 days 
after treatment, there were no abnormalities in the adjacent 
nerves, including the sciatic nerve. Another adverse event 
was a skin burn on Patient 4, who had right humerus bone 
metastasis from renal cell carcinoma. One day after the 
treatment, there were second degree skin burns on the right 
humerus and chest wall, the side opposite to where the 
transducer was placed. These burns resolved spontaneously 
within 1 week.
DISCUSSION
Our preliminary study suggests that MRgFUS using the 
ExAblate Conformal Bone System seems to be an effective 
palliative treatment in selected patients with painful bone 
metastases, without serious adverse events.
bone due to breast cancer, had difficulty in hip joint rotation 
and hardly walked. After treatment, her hip joint rotation 
became free, and her daily average walking distance in-
creased to 4 km. The other patients did not describe any 
movement limitations before or after treatment. 
Follow-up CT and MR imaging at 90 days after treatment 
were obtained for the two patients who completed the 
schedule. In Patient 2, the size of the enhancing soft tissue 
mass in the metastatic lesion had decreased, and a new bone 
formation was seen (Fig. 2). In Patient 3, the enhancing soft 
tissue mass did not significantly change in size; however, a 
non-perfusion area was seen at the anterior periosteum of 
the femur (Fig. 3).
Due to the anesthesia administered before the beginning 
of each treatment, all patients did not complain of any pain 
during the treatment. Although there were no severe ad-
verse events related to the ExAblate Conformal Bone Sys-
tem treatment, two minor adverse events were noted in this 
study. Patient 3 complained of sonication-related leg pain 
Fig. 2. Patient 2 with breast cancer. Comparison of (A) contrast-enhanced T1-weighted MR image before treatment, (B) contrast-en-
hanced T1-weighted MR image at 90 days after treatment; note the decrease in size of the enhancing mass, especially right to left diame-
ter. Comparison of (C) CT before treatment, (D) CT at 90 days after treatment; note the new bone formation (arrow). Further new bone for-
mation (arrow) was seen on (E) CT at 1 year after treatment. 
A
C
E
B
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tion of bone tissue is higher than that of soft tissue, and the 
penetration of ultrasonic energy into the bone can be mini-
mal. Due to the low thermal conductivity and high acoustic 
absorption rate of the bone cortex, MRgFUS for bone me-
tastases can be conducted using lower energy levels than 
MRgFUS for soft tissue tumors. This feature minimizes the 
thermal damage around the treated bone site while still 
achieving a localized heating effect.
In addition to volume reduction, new bone formation has 
been reported in several patients with osteolytic bone metas-
tasis treated with MRgFUS.8,11,12 A possible explanation for 
this observation is that thermal ablation by MRgFUS could 
lead to accelerated bone healing with subsequent sclerosis at 
the osteolytic lesion. In our study, one patient with osteolyt-
ic metastasis demonstrated new bone formation on 3-month 
follow-up CT and progressive formation on 1-year follow-
up CT. 
The thermal effect of high-energy focused ultrasound in-
duces cell death and tissue coagulation necrosis. MR ther-
mometry based on the shift in proton resonance frequency 
caused by temperature rise makes real-time thermal map-
ping possible.13-15 The integration of focused ultrasound with 
MR thermometry enables the system operator to target and 
treat metastatic bone lesions accurately and safely, avoiding 
destruction of surrounding normal tissue by using the real-
time closed loop control.
The device has a relatively high safety profile compared 
with alternatives. In our study, however, there were two ad-
verse events, though not serious. One patient with sonica-
tion-related leg pain was clinically suspected to have a tran-
The two patients with breast cancer showed complete re-
sponse lasting more than 1 year, despite the progression of 
the tumor burden at primary and other metastatic sites. Con-
sidering that there were no adverse events observed at 1 
year and that the procedure could be repeated as necessary, 
MRgFUS using the ExAblate Conformal Bone System can 
be a good treatment option, especially for patients with a 
long life expectancy.
Several previous studies reported the use of MRgFUS for 
pain palliation therapy performed on patients with bone me-
tastases. These studies reported that MRgFUS can be an ef-
fective palliative treatment for selected patients with painful 
bone metastases without device-related serious adverse 
events. In previous body system studies, however, occasion-
al difficulties were reported in positioning the patient over 
the water bath when bone lesions were in areas where place-
ment in contact with the treatment transducer was difficult. 
Moreover, previous treatments performed using fixed posi-
tion transducers could provoke pain during treatment by re-
quiring patients to lie on a painful body site.8,11 The ExAblate 
Conformal Bone System used in the present study overcame 
these limitations by using a flexible transducer assembly, 
thereby enabling easy and comfortable access to multiple 
anatomical locations and reducing positioning-related pain 
in patients. 
The mechanism of the analgesic effect on bone metasta-
sis is assumed to be mainly periosteal denervation induced 
by high ultrasound energy absorption of the bone cortex. 
Another possible mechanism could be a reduced mass ef-
fect by thermal ablation of the tumor. The acoustic absorp-
Fig. 3. Patient 3 with breast cancer. Comparison of (A) contrast-enhanced T1-weighted MR image before treatment, (B) contrast-en-
hanced T1-weighted MR image at 90 days after treatment; note the newly-developed linear, non-perfused area (arrows) at the anterior 
periosteum of the femur. 
A B
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ment. Pain 1997;69:1-18.
3. Rades D, Schild SE, Abrahm JL. Treatment of painful bone me-
tastases. Nat Rev Clin Oncol 2010;7:220-9. 
4. Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of 
metastatic bone pain: single fraction versus multifraction radio-
therapy--a systematic review of randomised trials. Clin Oncol (R 
Coll Radiol) 2003;15:345-52.
5. Callstrom MR, Charboneau JW, Goetz MP, Rubin J, Atwell TD, 
Farrell MA, et al. Image-guided ablation of painful metastatic 
bone tumors: a new and effective approach to a difficult problem. 
Skeletal Radiol 2006;35:1-15. 
6. Cole DJ. A randomized trial of a single treatment versus conven-
tional fractionation in the palliative radiotherapy of painful bone 
metastases. Clin Oncol (R Coll Radiol) 1989;1:59-62.
7. 8 Gy single fraction radiotherapy for the treatment of metastatic 
skeletal pain: randomised comparison with a multifraction sched-
ule over 12 months of patient follow-up. Bone Pain Trial Working 
Party. Radiother Oncol 1999;52:111-21.
8. Gianfelice D, Gupta C, Kucharczyk W, Bret P, Havill D, Clemons 
M. Palliative treatment of painful bone metastases with MR imag-
ing--guided focused ultrasound. Radiology 2008;249:355-63.
9. Saarto T, Janes R, Tenhunen M, Kouri M. Palliative radiotherapy 
in the treatment of skeletal metastases. Eur J Pain 2002;6:323-30.
10. Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus TP, 
Welch TJ, et al. Percutaneous image-guided radiofrequency abla-
tion of painful metastases involving bone: a multicenter study. J 
Clin Oncol 2004;22:300-6.
11. Liberman B, Gianfelice D, Inbar Y, Beck A, Rabin T, Shabshin N, 
et al. Pain palliation in patients with bone metastases using MR-
guided focused ultrasound surgery: a multicenter study. Ann Surg 
Oncol 2009;16:140-6. 
12. Napoli A, Anzidei M, Marincola BC, Brachetti G, Ciolina F, Car-
tocci G, et al. Primary pain palliation and local tumor control in 
bone metastases treated with magnetic resonance-guided focused 
ultrasound. Invest Radiol 2013;48:351-8.
13. Ishihara Y, Calderon A, Watanabe H, Okamoto K, Suzuki Y, Ku-
roda K, et al. A precise and fast temperature mapping using water 
proton chemical shift. Magn Reson Med 1995;34:814-23.
14. Chung AH, Jolesz FA, Hynynen K. Thermal dosimetry of a fo-
cused ultrasound beam in vivo by magnetic resonance imaging. 
Med Phys 1999;26:2017-26.
15. McDannold N, King RL, Jolesz FA, Hynynen K. The use of quan-
titative temperature images to predict the optimal power for fo-
cused ultrasound surgery: in vivo verification in rabbit muscle and 
brain. Med Phys 2002;29:356-65.
16. Hindley J, Gedroyc WM, Regan L, Stewart E, Tempany C, Hyny-
en K, et al. MRI guidance of focused ultrasound therapy of uterine 
fibroids: early results. AJR Am J Roentgenol 2004;183:1713-9.
17. Leon-Villapalos J, Kaniorou-Larai M, Dziewulski P. Full thick-
ness abdominal burn following magnetic resonance guided fo-
cused ultrasound therapy. Burns 2005;31:1054-5.
18. Stewart EA, Gedroyc WM, Tempany CM, Quade BJ, Inbar Y, Eh-
renstein T, et al. Focused ultrasound treatment of uterine fibroid 
tumors: safety and feasibility of a noninvasive thermoablative 
technique. Am J Obstet Gynecol 2003;189:48-54.
sient sciatic nerve injury. One of the known complications 
of MRgFUS is nerve injury due to the lower tolerance of 
nerves to the high temperature.16 The other adverse event in 
our study was a second degree skin burn on the side of the 
body opposite to where the transducer was positioned. There 
have been several reports of skin burns on the same side as 
the transducer due to entrapped air between the body and 
the transducer.17,18 However, our case shows a skin burn on 
the side opposite the transducer. This skin burn on the ante-
rior arm might be related to energetic sonications that were 
not fully intersecting the body tissue, causing far field heat-
ing due to reflection from the skin-air interface. Due to the 
relatively low frequency of the conformal bone transducer, 
there is a deeper penetration of the energy. There is no up-
per limit to the accumulated acoustic energy as the energy 
is nonionizing. Therefore, the treatment can be repeated as 
long as tissue temperature is kept at a safe level. This fea-
ture makes MRgFUS more effective and useful than exter-
nal-beam radiation therapy, which is currently considered 
as the standard treatment of bone metastases. Furthermore, 
MRgFUS does not require the insertion of any probe or 
needle into the patient, making the procedure completely 
noninvasive.
In conclusion, MRgFUS was shown to be a long-lasting, 
effective palliative treatment in selected patients with pain-
ful bone metastases. In addition to pain palliation, our re-
sults suggest MRgFUS as a potential treatment option for 
long-lasting local tumor control. 
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